These outcomes, together with a former report displaying that a small-molecule ACKR3 agonist CCX771 reveals anxiolytic-like conduct in mice,2 support the idea of targeting ACKR3 as a unique strategy to modulate the opioid process, which could open up new therapeutic avenues for opioid-similar disorders. Improve much healthier immune operate: https://charlieh405tze8.wikitron.com/user